{
    "2019-04-29": [
        [
            {
                "time": "",
                "original_text": "【中信建投医药|行业周报】业绩持续分化，甄选优质赛道和优质个股",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药",
                        "行业周报",
                        "业绩分化",
                        "优质赛道",
                        "优质个股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "后“年报季”聚焦高景气领域，关注业绩增长可持续性｜【光大医药·周报】",
                "features": {
                    "keywords": [
                        "年报季",
                        "高景气领域",
                        "业绩增长",
                        "可持续性",
                        "光大医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【泰格医药】财报点评：19Q1业绩略超预期，有望持续较高增长",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "财报",
                        "19Q1",
                        "业绩超预期",
                        "较高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【东吴医药】医药周观点20190429:基金医药持仓比例11.3%，较2018年略有提升，建议积极关注有业绩保障的公司",
                "features": {
                    "keywords": [
                        "东吴医药",
                        "医药周观点",
                        "基金持仓",
                        "11.3%",
                        "业绩保障"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}